# EDGAR Filing Document

**Accession Number:** 0001527728
**File Stem:** 0001731122-26-000759
**Filing Date:** 2026-5
**Character Count:** 11311
**Document Hash:** 370fc413598b2c2d1eb6019553bcee87
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001731122-26-000759.hdr.sgml**: 20260520

**ACCESSION NUMBER**: 0001731122-26-000759

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260520

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260520

**DATE AS OF CHANGE**: 20260520

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lunai Bioworks Inc.
- **CENTRAL INDEX KEY:** 0001527728
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 452259340
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38758
- **FILM NUMBER:** 261001762

**BUSINESS ADDRESS:**
- **STREET 1:** CENTURY CITY MEDICAL PLAZA
- **STREET 2:** 2080 CENTURY CITY EAST
- **CITY:** SUITE 906 LOS ANGELES
- **STATE:** CA
- **ZIP:** 90067
- **BUSINESS PHONE:** 45 39179840

**MAIL ADDRESS:**
- **STREET 1:** CENTURY CITY MEDICAL PLAZA
- **STREET 2:** 2080 CENTURY CITY EAST
- **CITY:** SUITE 906 LOS ANGELES
- **STATE:** CA
- **ZIP:** 90067

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RENOVARO INC.
- **DATE OF NAME CHANGE:** 20240213

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RENOVARO BIOSCIENCES INC.
- **DATE OF NAME CHANGE:** 20230807

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Enochian Biosciences Inc.
- **DATE OF NAME CHANGE:** 20230804

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **May 20, 2026**

**LUNAI BIOWORKS, INC.**

*(Exact name of registrant as specified in its charter)*

 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38758** | **45-2259340** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (I.R.S. Employer<br> Identification No.) |

---

**3400 Cottage Way, Suite G2, #3256**

**Sacramento, California 95825**

*(Address of principal executive offices)*

**+1 (424) 222-9301**

*(Registrant's telephone number, including area code)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of Each Class** | **Name of Each Exchange on Which Registered** |
| Common Stock, par value $0.0001 per share LNAI | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01. Other Events.**

On May 20, 2026, Lunai Bioworks, Inc. (the "**Company**") issued a press release announcing that it intends to effect a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share (the "Common Stock"), at a ratio of 1-for-8 (the "**Reverse Stock Split**"). The Reverse Stock Split is expected to become effective at 12:01 a.m. Eastern Time on May 22, 2026, and the Company's Common Stock is expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market at the opening of trading on May 22, 2026, under the existing trading symbol "LNAI."

The Company's Common Stock will trade under a new CUSIP number, 29350E302 following the effectiveness of the Reverse Stock Split.

A copy of the press release is filed herewith as Exhibit 99.1 and incorporated into this Item 8.01 by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 99.1 | [Press Release issued by Lunai Bioworks, Inc., dated May 20, 2026 (furnished herewith)](e7662_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **LUNAI BIOWORKS, INC.** | **LUNAI BIOWORKS, INC.** |
| By: | */s/ David Weinstein* |
| Name: David Weinstein | Name: David Weinstein |
| Title: Chief Executive Officer | Title: Chief Executive Officer |
| Date: May 20, 2026 | Date: May 20, 2026 |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**FOR IMMEDIATE RELEASE**

**LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT**

**SACRAMENTO, California — May 20, 2026 —** Lunai Bioworks, Inc. (Nasdaq: LNAI) (the "<u>Company</u>") today announced that it will effect a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share (the "<u>Common Stock</u>"), at a ratio of 1-for-8 (the "<u>Reverse Stock Split</u>"). The Reverse Stock Split is expected to become effective at 12:01 a.m. Eastern Time on May 22, 2026, and the Company's Common Stock is expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market at the opening of trading on May 22, 2026, under the existing trading symbol "<u>LNAI</u>."

The Company's Common Stock will trade under a new CUSIP number, 29350E302 following the effectiveness of the Reverse Stock Split.

At the Company's Special Meeting of Stockholders held on May 8, 2026, the Company's stockholders approved a proposal authorizing the Company's Board of Directors to amend the Company's Certificate of Incorporation to effect a reverse stock split of the Common Stock at a ratio in the range of 1-for-3 to 1-for-30, inclusive, with the exact ratio to be determined by the Board in its sole discretion and publicly announced prior to the effective time of the Reverse Stock Split. The Board of Directors subsequently approved the final 1-for-8 Reverse Stock Split ratio.

The Reverse Stock Split is intended primarily to increase the market price per share of the Company's Common Stock to assist the Company in regaining compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of at least $1.00 per share for continued listing on The Nasdaq Capital Market. The Company previously effected a 1-for-10 reverse stock split on September 30, 2025.

As a result of the Reverse Stock Split, every 8 shares of issued and outstanding Common Stock will automatically be combined into one issued and outstanding share of Common Stock. The Reverse Stock Split will not change the par value of the Common Stock or the number of authorized shares of Common Stock. The Reverse Stock Split will reduce the number of issued and outstanding shares of Common Stock from approximately 36,271,119 shares to approximately 4,533,890 shares, subject to adjustment for the treatment of fractional shares.

No fractional shares will be issued in connection with the Reverse Stock Split. Any fractional share that would otherwise result from the Reverse Stock Split will be automatically rounded up to the next whole share at the registered stockholder or DTC participant level, as applicable. Registered stockholders holding shares in book-entry form will receive information from the Company's transfer agent regarding their post-split holdings. Beneficial owners holding shares through a bank, broker or other nominee will have their positions adjusted in accordance with the procedures of their bank, broker or nominee.

The Company's transfer agent, Securities Transfer Corporation, will act as exchange agent for the Reverse Stock Split. Stockholders holding shares electronically in book-entry form are not required to take any action to receive post-split shares.

Proportionate adjustments will be made, as appropriate and in accordance with the terms of the applicable instruments, to the number of shares of Common Stock issuable upon the exercise, vesting, conversion or exchange of our outstanding options, warrants, restricted stock units and other convertible or exercisable securities, as well as to the exercise or conversion prices thereof and to share reserves under our equity compensation plans.

Lunai Bioworks (Nasdaq: LNAI) is an AI-driven life sciences company advancing drug discovery and chemical defense through its integrated platform. Lunai combines clinical data, machine learning, and in vivo validation to identify disease biology and develop precision therapeutics. The Company is focused on central nervous system diseases and oncology, with a mission to reduce development timelines and improve clinical success rates.

**Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements include, without limitation, statements regarding the expected timing and effectiveness of the Reverse Stock Split, the expected commencement of split-adjusted trading, the Company's ability to regain or maintain compliance with Nasdaq continued listing requirements, and the expected effects of the Reverse Stock Split on the Company's capitalization, trading price, liquidity and stockholders.These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including risks that the Reverse Stock Split may not result in a sustained increase in the market price of the Common Stock; may result in reduced liquidity, wider bid-ask spreads or increased volatility; may not enable the Company to regain or maintain compliance with Nasdaq Listing Rule 5550(a)(2) or other Nasdaq continued listing requirements; may be subject to Nasdaq, FINRA, DTC or other processing delays; and may be affected by general market conditions, trading prices, investor acceptance and the determinations of the Nasdaq Hearings Panel. Additional risks and uncertainties are described in the Company's filings with the U.S. Securities and Exchange Commission, including the risk factors in the Company's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

**Investor Contact**

Lunai Bioworks, Inc.

3400 Cottage Way, Suite G2, #3256

Sacramento, California 95825

Email: ir@lunaibioworks.com